GLP-1 Hair Loss: What Studies Show
Physician reveiwed October 4, 2026
Some GLP-1–based treatments increase the likelihood that participants report hair loss compared with placebo. A 2026 meta-analysis of nine studies quantified this difference: hair loss was reported about three times more often with treatment than with placebo.[3]
Research into GLP-1 hair loss spans clinical trials, patient surveys, and medical-record studies. The evidence supports an association with treatment, particularly for semaglutide and tirzepatide.[1–4]
Hair changes reported during GLP-1 treatment include diffuse shedding, patterned thinning, and breakage. These patterns can overlap: a period of shedding may make underlying androgenetic alopecia more noticeable.[13,14] Since hair loss has many possible causes, researchers are studying how weight loss, nutrition, and the medications themselves may contribute to these changes.
Key Takeaways
- Hair loss has been reported more often with certain GLP-1–based treatments than with placebo. The rate varies by medication, dose, population, and study.
- Telogen effluvium is an important explanation. Weight loss and changes in nutrient intake can disrupt the timing of the hair cycle.
- A direct medication effect remains an open question. Existing studies have not fully separated drug action from weight loss and other contributing factors.
- Texture changes deserve attention. Published survey data include dryness, breakage, and altered texture, but objective confirmation and causal evidence remain limited.
- Recovery depends on the diagnosis. Temporary shedding, progressive thinning, and hair-shaft breakage require different approaches.
Do GLP-1 Medications Cause Hair Loss?
Hair loss is a potential side effect of some GLP-1–based treatments. In clinical trials, participants reported it more often with treatment than with placebo.[1–3] Possible contributors include weight loss, reduced food intake, medication effects, and existing hair conditions. The timing and pattern of the hair change, together with a person’s health history, help a clinician assess what may be contributing.
These medications also provide important medical benefits. In randomized trials, tirzepatide produced significant weight loss; in the SELECT trial, semaglutide reduced major cardiovascular events among adults with cardiovascular disease and overweight or obesity without diabetes.[5,6]
Hair changes can affect a person’s confidence and well-being. Clinicians should consider each patient’s concerns alongside the benefits of GLP-1 treatment and the condition it treats.
What Are GLP-1 Medications, and How Do They Work?
Glucagon-like peptide-1, or GLP-1, is a hormone released by the intestine after eating. It helps coordinate insulin release, glucagon secretion, appetite, and stomach emptying.[7]. Its receptor receives that signal and activates responses inside the cell.
A receptor agonist is a substance that activates the receptor. The body’s active GLP-1 lasts only about 1–2 minutes before the enzyme DPP-4 breaks it down.[7] Semaglutide is a modified form of GLP-1 designed to resist that breakdown; it remains active for about a week, providing much longer receptor stimulation.[1] This sustained activity affects appetite and food intake and can lead to weight loss, which may disrupt the hair cycle. Researchers are also investigating whether prolonged GLP-1 signaling has direct effects on hair biology.
These actions explain their role in metabolic health. Some GLP-1–based medications are prescribed as weight loss drugs to help reduce body weight; their approved uses depend on the specific product.[1,2,7]
Two medications feature prominently in the hair-loss literature:
| Medication | Familiar brands | How it acts |
|---|---|---|
| Semaglutide | Ozempic, Wegovy | Activates the GLP-1 receptor |
| Tirzepatide | Mounjaro, Zepbound | Activates both GIP and GLP-1 receptors |
Semaglutide activates GLP-1. Tirzepatide is technically a dual GIP/GLP-1 receptor agonist. GIP is another hormone involved in the body’s response to food. GIP helps regulate insulin release and how the body processes nutrients after eating. In tirzepatide, GIP activity works alongside GLP-1 activity to affect appetite and body weight; weight loss and reduced food intake may contribute to hair shedding by disrupting the hair cycle.[2,5,9,10]
This distinction matters when interpreting hair-loss findings. Tirzepatide activates both GIP and GLP-1 pathways; semaglutide activates GLP-1. Researchers are studying how these pathways, along with treatment-related changes in appetite, food intake, and weight, may relate to reported hair loss.[2,5,9,10]
What Do Studies Show About GLP-1 Hair Loss?
Clinical trials and prescribing information
The Wegovy and Zepbound trial results show how often participants reported hair loss at specific doses, compared with placebo:
| Treatment and study setting | Reported hair loss with treatment | Reported hair loss with placebo |
|---|---|---|
| Wegovy 2.4 mg injection: pooled adult weight-management studies | 3.3% | 1% |
| Wegovy 7.2 mg injection: trials described in the current label | 5.8% | 1% |
| Zepbound 5, 10, or 15 mg: pooled adult weight-management studies | 5%, 4%, and 5%, respectively | 1% |
Sources: Wegovy and Zepbound prescribing information.[1,2]
These are reported adverse-event rates within specified trials. The percentages show how often participants reported hair loss in the specific trials listed. Each figure applies to the medication, dose, and study population shown.
Both prescribing labels link hair-loss reports with weight reduction. In Zepbound’s pooled adult weight-management studies, reported hair loss also differed by sex:
| Participants | Reported hair loss with Zepbound | Reported hair loss with placebo |
|---|---|---|
| Women | 7.1% | 1.3% |
| Men | 0.5% | 0% |
Source: Zepbound prescribing information, pooled Studies 1 and 2.[2]
The reason for this difference by sex requires further study.
What pooled research adds
A 2026 meta-analysis included nine interventional studies, seven of them randomized trials. Across 4,114 treated participants, the pooled risk ratio for hair loss compared with placebo was approximately 3.25, with a 95% confidence interval of 1.44–7.36.[3] (Participants receiving treatment were about three times as likely to report hair loss as those receiving placebo).
What medical-record studies can tell us
A 2026 propensity-matched TriNetX study found associations between semaglutide or tirzepatide use and non-scarring hair loss, including telogen effluvium at certain follow-up points. Patients with hair-loss outcomes had lower follow-up BMI than those without those outcomes, [4] but it did not establish that they had lost more weight.
Why the type of evidence matters
| Evidence type | What it contributes | Main limitation |
|---|---|---|
| Randomized trials | Treatment-versus-placebo comparisons | Hair loss is often recorded without detailed scalp diagnosis |
| Medical-record cohorts | Associations with diagnosed conditions over time | Residual confounding and incomplete records |
| Adverse-event databases | Reports that can identify emerging safety concerns | Reporting frequency cannot establish incidence or causation |
| Patient surveys | Experiences such as shedding, dryness, and texture changes | Self-report and participant selection |
| Systematic reviews | A structured synthesis of available studies | Conclusions depend on the quality and overlap of the included evidence |
An earlier analysis of reports from several safety databases found no strong hair-loss signal, even though some reports had been filed.[8] Differences in the time periods, comparison groups, and reporting methods can lead studies to different results.
Possible Reasons for Hair Shedding During GLP-1 Treatment
Rapid weight loss and a shift in the hair cycle
Hair follicles alternate between growth, transition, rest, and shedding. A significant physiological change can cause more follicles to leave growth earlier than usual, producing diffuse shedding after a delay. This is called telogen effluvium.[9]
In telogen effluvium, more follicles shift from the active growth phase into the resting phase before shedding. Rapid or significant weight loss is one recognized trigger.[9,10]
Weight-loss-associated shedding existed before GLP-1 medications. A retrospective study of 140 patients with telogen effluvium following weight loss documented this relationship across different causes of weight reduction.[10] Because the study enrolled patients who already had the condition, it cannot tell us what proportion of all people losing weight will develop it.
The hair growth cycle helps explain why shedding may become noticeable weeks or months after a trigger.
Changes in calorie, protein, or micronutrient intake
Appetite suppression, nausea, or difficulty tolerating food can reduce how much a person eats and make it harder to meet nutritional needs.
Eating less does not by itself mean someone has a nutrient deficiency. The key question is whether reduced intake has left the person short of energy, protein, or specific nutrients needed for hair growth. Iron, zinc, and other deficiencies can contribute to some forms of hair loss, though the value of supplementation depends on the nutrient and whether a deficiency is present.[11]
Assessing protein intake and, when appropriate, checking for deficiencies can help identify a nutritional problem that needs treatment.
Could GLP-1 receptor activity relate to patterned hair loss?
A 2026 genetic study estimated that higher genetically predicted GLP-1 receptor expression was associated with 7% higher odds of male-pattern hair loss.[17] The researchers analyzed genetic data, not people taking GLP-1 medications. The finding suggests a possible biological link, but it does not establish that these medications cause patterned hair loss or show whether the association applies to women.
Could the medication affect hair biology directly?
The September 2026 review Hair and Scalp Effects of GLP-1 Receptor Agonists in Practice discusses several possible contributors to hair changes: reduced calorie or nutrient intake, hormonal shifts during weight loss, and changes in dermal white adipose tissue, a layer of fat cells in the skin closely associated with hair follicles.[12] This tissue helps shape the follicles’ local environment and provides signals that may influence the hair cycle. The review raises the possibility that weight-loss-related changes or GLP-1 receptor activity could alter those signals and affect follicle activity.
These pathways remain under investigation. Most evidence that incretin-based therapies alter fat tissue comes from subcutaneous fat, not the distinct dermal fat around hair follicles. Researchers have not established whether treatment changes this follicle-associated tissue in humans or whether such changes contribute to hair loss.[12,19] Studies that track scalp and hair findings alongside weight, nutrient status, and medication exposure from before treatment could help distinguish these possibilities.
Is It Shedding, Progressive Thinning, or Hair Breakage?
GLP-1 studies often record “hair loss” without identifying a specific diagnosis. Diffuse shedding, gradual thinning, hair breakage, and patchy or inflamed scalp changes can have different causes. Identifying the pattern helps clarify what study reports may represent and what needs clinical assessment.
| Pattern | What someone might notice | What needs assessment |
|---|---|---|
| Telogen effluvium | Increased shedding across the scalp | Recent triggers and a possible shift in the hair cycle |
| Androgenetic alopecia | Gradual widening of the part, crown thinning, or recession | Patterned thinning and follicle miniaturization |
| Hair breakage | Short, snapped strands or uneven lengths | Hair-shaft damage and exposure to heat, chemicals, or tension |
| Patchy loss or an inflamed scalp | Localized bald areas, pain, redness, or flaking | Scalp examination for other conditions |
These patterns can overlap. A period of diffuse shedding may make underlying androgenetic alopecia more noticeable. A 2026 review of 24 primary studies identified both telogen effluvium and androgenetic alopecia among reported diagnoses, although many studies did not specify a hair-loss subtype.[13]
Hair breakage occurs along the strand. It can reduce hair length or fullness without increased shedding from the follicle, so it is a different change to assess when interpreting reports of hair loss during GLP-1 treatment.
Early conference evidence on scalp symptoms: In the SCOP-GLP1 cross-sectional survey presented by Laboratoires Ducray at the 2026 EADV Congress, 65.2% of 575 GLP-1-treated participants reported hair loss, compared with 35.3% of unexposed participants with metabolic conditions. Among treated participants who reported hair loss, 59.7% also reported itching, redness, or flaking.[18] These self-reported findings are not rates for all GLP-1 users, and the survey cannot show that treatment caused the hair loss or scalp symptoms. They underscore why scalp symptoms should be assessed separately from shedding.
Can GLP-1 Medications Change Hair Texture, Dryness, or Strength?
Published patient reports include changes beyond shedding. A 2026 US cross-sectional survey of 504 GLP-1 or dual GIP/GLP-1 medication users recorded the following:[14]
| Reported change | Percentage of the surveyed sample |
|---|---|
| Increased shedding | 20.8% |
| Thinning | 19.0% |
| Dryness | 8.5% |
| Breakage | 7.9% |
| Brittleness | 3.6% |
| Texture changes | 3.6% |
| Hair shape changes, such as curly to straight or straight to curly | 2.2% |
Participants could report more than one change, so categories may overlap. These percentages describe the survey respondents, not all people taking these medications.
The survey was predominantly female, relied on self-report, and did not objectively measure hair fibers. The authors disclosed employment at L’Oréal Research & Innovation.[14] The results capture participants’ experiences but cannot establish whether medication, weight loss, nutrition, or another factor caused the reported changes.
Future studies should track participants before and during GLP-1 treatment, recording shedding, thinning, breakage, and texture changes separately. Standardized scalp photographs and examinations, combined with direct measurements of hair-fiber diameter, strength, and shape, could show which reported changes correspond to measurable differences and how they relate to treatment, weight loss, and nutrition.
Hair Regrowth After GLP-1–Associated Hair Loss
Recovery depends on the cause. Telogen effluvium is a nonscarring condition, so the follicles retain their capacity to produce hair. Acute episodes often improve after the trigger resolves.[9]
In a study of 140 people with hair loss after weight loss, improvement occurred without treatment, with an average time to improvement of about five months.[10] This was not a GLP-1 study, and its average does not predict how quickly an individual’s hair will recover or regain fullness.
Ongoing triggers, nutritional deficiencies, or coexisting pattern hair loss can affect recovery. Reduced shedding and restored fullness are separate milestones.
GLP-1-specific studies have not yet established long-term recovery timelines, particularly for people who continue treatment.
What Can You Do if You Notice Hair Changes?
Build a timeline
Record when treatment started, when doses changed, when weight loss accelerated, and when the hair change began. Include recent illness, surgery, other medications, and major dietary changes.
Take photographs in consistent lighting. Note whether the change involves shedding, a widening part, broken strands, or altered texture. These details can help a clinician assess the pattern and timing.
Identify the condition and contributing factors
Assessment begins with a health history and scalp examination. Depending on the findings, a clinician may check for anemia, low iron, thyroid problems, or other nutritional concerns. Testing should reflect the individual’s situation.[15]
Discuss substantial or persistent hair changes with the prescriber and a dermatologist. Any medication adjustment should account for the treatment’s purpose, benefits, and possible side effects.
Patterned thinning, persistent itching, redness or flaking, patchy loss, scalp pain, or rapidly worsening changes warrant clinical evaluation. A clinician can assess whether these signs point to a condition that needs specific care.
Maintain nutritional adequacy
Reduced appetite or difficulty tolerating food can make it harder to get enough calories and protein. A dietitian can help plan food intake around a person’s tolerance and health needs.
Correct a confirmed deficiency rather than adding supplements without a clear need. Excess vitamin A or selenium can contribute to hair loss.[11] Addressing a deficiency may support hair growth when that deficiency is a factor, but it does not show that supplements prevent GLP-1-associated shedding.[11,13]
Choose treatment based on the diagnosis
Treatment for telogen effluvium focuses on identifying and addressing contributing factors. Coexisting pattern hair loss may need separate treatment.
Some botanical-containing supplements have been studied in chronic telogen effluvium, but the evidence does not establish a treatment for GLP-1-associated shedding. A 2025 placebo-controlled trial tested a formula containing saw palmetto and pumpkin seed, as well as L-cystine, Pygeum, vitamins, and minerals, in people with chronic telogen effluvium or androgenetic alopecia. Because it tested a combination of ingredients, the study cannot identify the effect of any one botanical. It also did not study GLP-1 users or recovery after weight-loss-related shedding.[20]
A September 2026 clinical review discusses low-dose oral minoxidil as one treatment option.[12] Oral minoxidil is an off-label hair-loss treatment that requires medical assessment. The review does not establish it as a GLP-1-specific prevention strategy or as the right option for every patient.
Reduce avoidable hair-fiber damage
While the cause of hair changes is being assessed, everyday care can support scalp comfort and limit avoidable stress on fragile strand. Gentle detangling and less heat, chemical processing, and tension reduce fiber damage; conditioner can lower friction during combing.[16] To match routine care to concerns such as thinning or shedding, scalp condition, or fragile strands, try Origenere’s Hair Growth Regimen Finder.
What Do We Still Need to Learn?
| What current evidence supports | What remains uncertain |
|---|---|
| Certain treatments had more reported hair loss than placebo in clinical trials | How much of the association relates to weight loss versus medication effects |
| Medical-record studies report associations with nonscarring hair-loss diagnoses | Individual risk and the rate of hair loss in routine care |
| Weight loss can trigger telogen effluvium | How weight-loss speed, dose, and nutrient intake affect each person |
| Patients report dryness, breakage, and texture changes | Whether objective hair-fiber changes occur, what causes them, and whether they reverse |
| Assessment can identify nutritional problems that need treatment | Which interventions improve GLP-1-associated hair outcomes |
Prospective studies should begin before treatment and include baseline scalp examinations, standardized photographs, nutritional measurements, and repeated hair assessments. Comparing participants with people who lose similar amounts of weight through other approaches could help researchers separate medication effects from weight-loss effects. Treatment trials are also needed to determine which strategies improve hair outcomes.
Frequently Asked Questions
Does Ozempic cause hair loss?
Semaglutide has been associated with hair-loss reports, but rates vary by product, dose, and study population. Wegovy trial figures do not establish an Ozempic-specific rate. Assessment should consider weight change, nutrition, and other possible causes.[1,4]
What do studies show about Wegovy, Mounjaro, and Zepbound?
Wegovy and Zepbound prescribing information record hair-loss events in weight-management trials. Mounjaro and Zepbound contain tirzepatide, but their indications and trial populations differ. Trial rates apply to the specific products, doses, and groups studied.[1,2]
Does hair loss during GLP-1 treatment always mean temporary shedding?
No. Telogen effluvium is one reported pattern, but hair changes may also involve androgenetic alopecia, breakage, or another scalp condition. The pattern and clinical assessment help identify what is happening.[9,13]
Can hair loss be prevented during GLP-1 treatment?
Maintaining adequate nutrition and identifying contributing conditions are reasonable priorities. Research has not established a reliable prevention plan for everyone taking GLP-1 medications.[13]
Can GLP-1 medications change hair texture?
People have reported texture changes, dryness, and breakage in a survey. The survey did not objectively measure hair fibers, so it cannot establish what caused those changes.[14]
Can shampoo or hair vitamins stop medication-associated shedding?
Shampoo and conditioner can cleanse the scalp and support strand condition. Supplements can address specific nutritional needs. Neither is established as a general treatment for GLP-1-associated shedding; care should match the diagnosis.[11,16]
A Thoughtful Approach to Hair Changes
Hair changes during GLP-1 treatment call for identifying the pattern, assessing relevant contributing factors, and matching care to the diagnosis.
Scientific References
- FDA. Wegovy prescribing information. Revised June 2026; Section 6.1.
- DailyMed. Zepbound prescribing information. Section 6.1; accessed October 4, 2026.
- Cheng PL, Chang HC. Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis. Diabetes Research and Clinical Practice. 2026;237:113333.
- Nonscarring Alopecia in Adults Treated With GLP-1s: A Propensity Score Matched TriNetX Cohort Study. The Laryngoscope. 2026.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387:205–216.
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023;389:2221–2232.
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. 2018;27:740–756.
- Nakhla M, et al. Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study. Cardiovascular Drugs and Therapy. 2025;39:1331–1341.
- Malkud S. Telogen Effluvium: A Review. Journal of Clinical and Diagnostic Research. 2015;9:WE01–WE03.
- Kang DH, et al. Telogen Effluvium Associated With Weight Loss: A Single Center Retrospective Study. Annals of Dermatology. 2024;36:384–388.
- Almohanna HM, et al. The Role of Vitamins and Minerals in Hair Loss: A Review. Dermatology and Therapy. 2019;9:51–70.
- Bridges AG, Jackson T. Hair and Scalp Effects of GLP-1 Receptor Agonists in Practice. Clinics in Dermatology. Published online September 21, 2026. Abstract consulted.
- Gupta AK, et al. GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling. Science Progress. 2026;109(2).
- Olivero JW, et al. Dermatological, Trichological and Quality of Life Consequences of GLP-1 Receptor Agonist-Mediated Weight Loss: A US Cross-Sectional Survey. Journal of Cosmetic Dermatology. 2026;25:e71145.
- Yin GOC, Siong-See JL, Wang ECE. Telogen Effluvium – a review of the science and current obstacles. Journal of Dermatological Science. 2021;101:156–163.
- Gavazzoni Dias MFR. Hair Cosmetics: An Overview. International Journal of Trichology. 2015;7:2–15.
- Ramessur R, Spindler A, Maas D, et al. A causal effect of increased GLP1R expression on male-pattern hair loss is suggested by 2-sample Mendelian randomization. Journal of Investigative Dermatology. 2026. doi: 10.1016/j.jid.2026.07.024.
- Laboratoires Pierre Fabre / Laboratoires Ducray. SCOP-GLP1 survey: reported hair and scalp findings among participants treated with GLP-1. Company news release announcing presentation at the European Academy of Dermatology and Venereology Congress. October 2, 2026.
- Gupta AK, Kaur J, Piguet V, Mirmirani P. Adipocytes as a Mechanistic Link Between Incretin-Based Therapies and Hair Loss. Biology. 2026;15(18):1642.
- Piquero-Casals J, Saceda-Corralo D, Aladren S, et al. Oral Supplementation with l-Cystine, Serenoa repens, Cucurbita pepo, and Pygeum africanum in Chronic Telogen Effluvium and Androgenetic Alopecia: A Double-Blind, Placebo-Controlled, Randomized Clinical Study. Skin Appendage Disorders. 2025;11(1):27–35. doi: 10.1159/000540081.
Leave a comment